JYNARQUE® (tolvaptan) may help change the course of your disease

JYNARQUE is the first-and-only FDA-approved treatment proven to slow kidney function decline in adults who are at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)

JYNARQUE slows the decline in kidney function

1 yea r star t Stage 3b Stage 3a Stage 4 mL/min/1.73m2 3 0 4 5 Speed of decline slowed by more than 35%. Average eGFR over time Difference JYNARQUE made JYNARQUE Placebo *Kidney function was measured by estimated glomerular filtration rate (eGFR). In a clinical trial of ADPKD patients with chronic kidney disease (CKD) stages 2-4, kidney function, or eGFR, was 1.3 higher on average for people taking JYNARQUE than for people taking placebo at the end of the 1-year study.*
Difference JYNARQUE made JYNARQUE Placebo 1 yea r star t Stage 3b Stage 3a Stage 4 mL/min/1.73m2 3 0 4 5 Speed of decline slowed by more than 35%. Average eGFR over time *Kidney function was measured by estimated glomerular filtration rate (eGFR). In a clinical trial of ADPKD patients with chronic kidney disease (CKD) stages 2-4, kidney function, or eGFR, was 1.3 higher on average for people taking JYNARQUE than for people taking placebo at the end of the 1-year study.*
Difference JYNARQUE made JYNARQUE Placebo 1 year start 2 years 3 years Stage 3b Stage 3a Stage 4 mL/min/1.73m2 3 0 4 5 Average eGFR over time Speed of decline slowed by more than 26%. In a clinical trial of ADPKD patients with CKD stages 1-3, patients taking JYNARQUE had greater kidney function (eGFR was 3.26 higher) than the patients who were taking placebo at the end of the 3-year study.
CHART 2 Created with Sketch. Difference JYNARQUE made JYNARQUE Placebo 1 year start 2 years 3 years Stage 3b Stage 3a Stage 4 mL/min/1.73m2 3 0 4 5 Average eGFR over time Speed of decline slowed by more than 26%. In a clinical trial of ADPKD patients with CKD stages 1-3, patients taking JYNARQUE had greater kidney function (eGFR was 3.26 higher) than the patients who were taking placebo at the end of the 3-year study.

Patients taking JYNARQUE had less kidney pain

In a clinical trial of ADPKD patients with CKD stages 1-3,

patients taking JYNARQUE had

36% fewer pain events

requiring medication or other treatment than those taking placebo.

 

Treatment was defined as:

  • Prescribed leave
  • Surgery
  • Radiologic treatment

JYNARQUE works at different stages of disease

JYNARQUE is for people at risk of having fast-progressing ADPKD.

JYNARQUE is appropriate in adults at stages 1-4 of CKD with rapidly progressing disease. Whether your GFR is 90 or 30, JYNARQUE may help.

2 3 4 1 STAGES OF CKD Study 1 Study 2
4 3 2 1 Study 1 Study 2 STAGES OF CKD

JYNARQUE is a long-term treatment that has been studied in many patients

  • JYNARQUE has been studied in over 3000 people with ADPKD
  • For people who do not have kidney failure, JYNARQUE may help by slowing the loss of function for as long as they keep taking it
  • JYNARQUE may change the course of your disease by slowing kidney function decline as it works over a period of years. As you take JYNARQUE, remember that it is a long-term treatment and can take time to make a difference

INDICATION AND IMPORTANT SAFETY INFORMATION